Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Wigger, A; Sanchez, MM; Mathys, KC; Ebner, K; Frank, E; Liu, D; Kresse, A; Neumann, ID; Holsboer, F; Plotsky, PM; Landgrafl, R.
Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin.
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Kresse Adelheid

Dimensions Citations:

Plum Analytics:
To model aspects of trait anxiety/depression, Wistar rats were bred for extremes in either hyper (HAB)- or hypo(LAB)-anxiety as measured on the elevated plus-maze and in a variety of additional behavioral tests. Similar to psychiatric patients, HAB rats prefer passive stress-coping strategies, indicative of depression-like behavior, show hyper-reactivity of the hypothalamo-pituitary-adrenal axis, and a pathological response to the dexamethasone/corticotropin-releasing hormone (CRH) challenge test. Here we tested central mRNA expression, release patterns, and receptor binding of neuropeptides critically involved in the regulation of both anxiety-related behavior and the HPA axis. Thus, CRH, arginine-8-vasopressin (AVP), and oxytocin (OXT) were studied in brains of HAB and LAB males both under basal conditions and after exposure to a mild emotional stressor. In HAB rats, CRH mRNA was decreased in the bed nucleus of the stria terminalis only. While no significant difference in CRH1-receptor binding was found in any brain area, CRH2-receptor binding was elevated in the hypothalamic paraventricular nucleus (PVN), the ventromedial hypothalamus, and the central amygdala of HABs compared to LABs. AVP, but not OXT, mRNA expression as well as release of the neuropeptide, were higher in the PVN of HABs, whereas AVP V1a-receptor binding failed to show significant differences in any brain region studied. Remarkably, intra-PVN treatment of HABs with the AVP V1-receptor antagonist d (CH(2))(5) Tyr (Me) AVP resulted in a decrease in anxiety/depression-related behavior. The elevated expression and release of AVP within the PVN of HAB rats together with the behavioral effects of the AVP V1-receptor antagonist suggest a critical involvement of this neuropeptide in neuroendocrine and behavioral phenomena associated with trait anxiety/depression.
Find related publications in this database (using NLM MeSH Indexing)
Analysis of Variance -
Animals -
Anxiety - genetics Anxiety - metabolism
Autoradiography - methods
Behavior, Animal -
Binding Sites -
Breeding -
Central Nervous System - anatomy and histology Central Nervous System - metabolism
Corticotropin-Releasing Hormone - genetics Corticotropin-Releasing Hormone - metabolism
Disease Models, Animal -
Exploratory Behavior -
Gene Expression -
Genetics, Behavioral -
In Situ Hybridization -
Male -
Maze Learning -
Microdialysis - methods
Neuropeptides - genetics Neuropeptides - metabolism
Oxytocin - genetics Oxytocin - metabolism
Protein Binding -
RNA, Messenger - metabolism
Rats -
Rats, Inbred Strains - genetics
Rats, Wistar -
Reaction Time -
Receptors, Corticotropin-Releasing Hormone - metabolism
Receptors, Neuropeptide - genetics Receptors, Neuropeptide - metabolism
Receptors, Vasopressin - antagonists and inhibitors
Stress, Physiological - metabolism
Swimming -
Time Factors -
Vasopressins - genetics Vasopressins - metabolism Vasopressins - physiology

Find related publications in this database (Keywords)
© Med Uni Graz Impressum